Recent investigations have converged on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic communication. While GIP agonists are commonly employed for treating type 2 diabetes, their emerging effects on reward circuits, specifically governed by dopaminergic pathways, are receiving